The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients-Reference-Cited by-同舟云学术

The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients

Published:2015-11-11 Issue:3 Volume:172 Page:420-427
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kurtovic-Kozaric Amina¹²³,Hasic Azra²,Radich Jerald P.⁴,Bijedic Vildan⁵,Nefic Hilada²,Eminovic Izet²,Kurtovic Sabira⁵,Colakovic Ferida⁶,Kozaric Mirza⁷³,Vranic Semir¹,Bovan Nada S.⁸

Affiliation:

1. Department of Pathology; University Clinical Centre Sarajevo; Sarajevo Bosnia and Herzegovina

2. Department of Biology; Faculty of Natural Sciences; University of Sarajevo; Sarajevo Bosnia and Herzegovina

3. Department of Genetics and Bioengineering; International Burch University; Sarajevo Bosnia and Herzegovina

4. Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle WA USA

5. Haematology Clinic; University Clinical Centre Sarajevo; Sarajevo Bosnia and Herzegovina

6. Haematology Clinic; Cantonal Hospital Zenica; Zenica Bosnia and Herzegovina

7. Centre for Mother and Child; University Clinical Centre Sarajevo; Sarajevo Bosnia and Herzegovina

8. Department of Internal Medicine; Clinical Hospital Mostar; Mostar Bosnia and Herzegovina

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13843/fullpdf

Reference16 articles.

1. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet;Baccarani;Journal of Clinical Oncology,2009

2. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

3. Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study;Bengió;Leukemia & Lymphoma,2011

4. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib;Deininger;Blood,2009

5. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia;Druker;New England Journal of Medicine,2001

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical trials in Bosnia and Herzegovina: Challenges and future perspectives;Contemporary Clinical Trials Communications;2022-08

2. A Ten-Year Experience of Treating Chronic Myeloid Leukemia in Rural Rwanda: Outcomes and Insights for a Changing Landscape;JCO Global Oncology;2022-07

3. Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study;Journal of Cancer Research and Clinical Oncology;2021-07-28

4. Clinical Outcomes of CML Patients After Delayed Start of Nilotinib Treatment;International Journal of Hematology and Oncology;2021-03-30

5. Epidemiology of Chronic Myeloid Leukaemia;Hematologic Malignancies;2021